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Role of Nuclear Receptors  
Peroxisome Proliferator-Activated Receptors 
(PPARs) and Liver X Receptors (LXRs) in the 
Human Placental Pathophysiology 




The placenta is a transitory structure indispensable for the proper development of the 
embryo and fetus during mammalian gestation. Like other members of the nuclear receptor 
family, the peroxisome proliferator-activated receptors (PPARs) and the liver X receptors 
(LXRs) are known to be involved in the physiological and pathological events occurring 
during the placentation. This placental involvement has been recently confirmed focusing 
on the early stages of placental development (implantation and invasion....), mouse 
knockout phenotypes and cyto/syncytio-trophoblastic physiology. In this review, we 
describe the involvement of PPARs and LXRs in placenta and in the amniotic membrane 
during gestation (e.g., fat transport and metabolism...), in pathological process (e.g., 
chorioamnionitis, preeclampsia...), metabolic disorders (e.g., diabetes) and parturition. 
2. The peroxisome proliferator-activated receptors (PPARs) 
Discovered in 1990, PPARs are known for their biological role in inducing the proliferation of 
peroxisomes in rodents (Issemann & Green, 1990). They are transcription factors belonging to 
the ligand-activated nuclear hormone receptor superfamily (Michalik et al., 2002) and have 
been identified in different species such as the xenopus, mouse, rat, and humans. 
2.1 Nomenclature and structure of PPARs 
In all these species, PPARs present three isotypes encoded by distinct single-copy genes: 
PPARǂ (NR1C1), PPARǃ/ǅ (also called NUC1 or NR1C2), and PPARǄ (NR1C3), located on 
chromosomes 22, 6, 3 in humans. The PPARǄ gene alternative promoters give rise to three 
different isoforms named Ǆ1, Ǆ2, and Ǆ3 which differ at their 5_ends (Fajas et al., 1997). 
PPAR ǂ, ǃ, Ǆ1/Ǆ3, Ǆ2 translation produces proteins of 468, 441, 475, and 505 amino acids, 
respectively, with a molecular weight of 49 to 56 kDa (Fournier et al., 2007). By performing 
multiple PPAR nucleotide/protein alignments in different species, a strong interspecies 
identity (human, mouse, rat, bovine, ≈84%) has been established, illustrating a strong 
evolutionary conservation among species by derivation from a common ancestor (Table 1). 
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Like several other members of the nuclear receptor superfamily, PPARs possess the typical 
structure organized in six domains named A to F (Figure 1) (Escher et al., 2000). Domain C 
(DBD: DNA binding domain) contains two zinc fingers and allows promoter target genes 
interaction and dimerization with its preferential nuclear receptor: retinoid X receptor 
(RXR). The PPAR/RXR heterodimer binds to the target gene promoter response element 
named peroxisome proliferator response element (PPRE) which is made up of two half site 
AGGTCA separated by one or two nucleotides (also called DR1 or DR2 for direct repeat 1 or 
2). Domain E/F allows ligand binding and contains a ligand-dependent transactivation 
function called AF2 (activating function 2). It is also involved in dimerization and 
interaction with cofactors. 
 
Table 1. Percentage of nucleotide and amino acid identity between human and mouse, rat 
and bovine PPAR sequences respectively. No PPARǄ3 alignment was carried out owing to 
lack of data on different species. The different sequences came from Ensembl and were 
aligned with Genomatix software (Borel et al., 2008). 
 
Fig. 1. Schematic representation of typical nuclear receptor structure. AF1: activating 
function 1 (ligand-independent function), AF2: activating function 2 (ligand-dependent 
function), NLS: nuclear signal localization (Borel et al., 2008). 
2.2 PPAR ligands 
As with the other nuclear receptors, the binding of the ligand is a key step in the control of 
PPAR transcriptional activity. In the absence of a ligand, corepressors and histone 
deacetylases (HDAC) bind to PPARs and inhibit the transcription of target genes. PPAR 
ligands have the ability to dissociate the corepressor complexes from the PPAR/RXR 
heterodimer, allowing the binding of the coactivators in order to initiate and activate 
transcription. There are two kinds of ligands for the PPARs: natural and synthetic. Among 
the natural ligands the monounsaturated fatty acids (FA) (e.g., oleic acid) and the 
polyunsaturated fatty acids (PUFA) (e.g., linoleic acid, linolenic acid and arachidonic acid) 
are described as ligands for PPARǂ, PPARǃ and PPARǄ. They act with concentrations 
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consistent with those found in human serum (Desvergne & Wahli, 1999). The different 
PUFA metabolites: 8(S)- and 15-hydroxyeicosatetraenoic acid (8(S)- and 15-HETE), 
leukotriene B4 (LTB4), 9- and 13- hydroxyoctadedienoic acid (9-HODE and 13-HODE) and 
15-deoxy-Δ12,14-prostaglandin J2 (PGJ2) are potent selective activators of PPARǂ and 
PPARǄ. 
More recently, it has been demonstrated that P450 eicosanoids are potent PPARǂ and 
PPARǄ ligands (Ng et al., 2007). These ligands induce PPAR binding to PPRE and can 
modify the expression of PPAR responsive genes like apoA-I or apoA-II in the same way 
than synthetic ligands. Thus the finely regulated conversion of PUFAs to eicosanoids 
through either the lipoxygenase, cyclooxygenase, or cytochrome P450 monooxygenase 
pathways may provide a mechanism for the differential regulation of PPARǂ and PPARǄ 
and their respective target genes. PPARǃ can be activated by different types of eicosanoids 
including prostaglandinA1 (PGA1) and prostaglandin D2 (PGD2). Many synthetic ligands 
exist and have been used in PPAR work. These ligands include prostaglandin 12 analogs, 
pirinixic acid (Wy-14643) for PPARǂ, hypolipidemic and hypoglycemic agents 
(nonthiazolidinedione) for PPARǃ, and thiazolidinediones (e.g., rosiglitasone, troglitazone) 
for PPARǄ (Michalik et al., 2002). 
2.3 Placental PPAR expression patterns 
The three PPAR isoforms are been shown to be expressed in the villous trophoblastic cells 
and syncytiotrophoblasts of the human term placenta (Fournier et al., 2007). Furthermore, 
the three PPARs are present in total placenta, amnion, chorion, and in amnion-derived 
WISH epithelial cell line at the mRNA and protein levels. But the expression of PPARǂ and 
PPARǄ seems to be weaker than that observed for PPARǃ/ǅ. In addition, PPARǄ is more 
express in chorion than in amnion (Borel et al., 2008). 
2.4 Implications of PPARs in placenta and fetal membranes 
2.4.1 Placental and amniotic presence of PPARs ligands 
The lipids of human amnion and chorion are enriched in the essential fatty acid arachidonic 
acid, which is the precursor of all the prostaglandins of the 2 series (Schwarz et al., 1975). 
Sixty-six percent of the arachidonic acid of the human fetal membranes are available in the 
glycerophospholipids of these tissues and can easily be converted into PGD2 (Okita et al., 
1982). The placenta produces considerable amounts of PGD2 (Mitchell et al., 1982). The 
enzymes necessary to convert PGD2 into prostaglandin J2 (PGJ2) are present and co 
expressed with PPARǄ in placenta. 15 Deoxy-Δ12,14-PGJ2 (15dPGJ2) and its precursor 
PGD2 are present in amniotic fluid at concentrations that do not exceed 3 nM (Helliwell et 
al., 2006). However, this amniotic fluid concentration cannot be an exact representation of 
the physiological placental reality for PPARs ligands because the nuclear concentration is 
not measured. The maternal blood may also be a source of PPAR ligands for the human 
placenta and the fetal membranes. It has been established that a heatstable compound (not a 
protein, but rather a prostanoid or a fatty acid) is detected in maternal blood serum and is 
able to activate the PPARǄ (Waite et al., 2000). The presence of classical and new PPARs 
ligands (e.g., P450 eicosanoids, PUFA metabolites) in placenta and fetal membranes suggests 
that they could activate PPAR, induce PPAR binding to PPREs and modify the expression of 
PPAR target genes. 
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2.4.2 Fundamental implications of PPARs during early placentation 
As a determining result, the knockout of the PPARǄ in mice (Barak et al., 1999) yielded the 
first findings indicating the importance of this factor in early embryonic and perinatal 
development. These results are concomitant with those obtained by the generation of RXRǂ 
or ǃ null mice (PPARǄ partner in the functional heterodimer), also showing an embryonic 
lethality explained by the lack of generation of a functional labyrinthine zone (Sapin et al., 
2001; Parrast et al., 2009). Furthermore, complementary studies conducted by the 
inactivation of PPARǄ coactivators or coregulators, such as peroxisome proliferators 
activator receptor-binding protein (PBP) and peroxisome proliferator-activated receptor-
interacting protein (PRIP), also lead to severe placental dysfunction, such as inadequate 
vascularisation of the structure (Antonson et al., 2003; Zhu et al., 2000; Zhu et al., 2003). 
Furthermore, the inactivation of PPARǃ/ǅ led to the formation of abnormal gaps and a 
thinner but fully differentiated vascular structure in the placentodecidual interface (Barak et 
al., 2002). These results establish the no redundant roles of PPARǄ and PPARǃ/ǅ in early 
mouse placental development. Recent analysis of PPAR null mice also demonstrated that 
PPAR plays a pivotal role in controlling placental vascular proliferation and contributes to 
its termination in late pregnancy [Nadra et al., 2010]. In human, PPARǃ/ǅ plays a central 
role at various stages of pregnancy like implantation, decidualization, and placentation 
(Wang et al., 2007). By contrast, the inactivation of PPARǂ has no effect on placental 
formation or on the developing fetus and by the way theirs possible roles during pregnancy 
had to be clarified (Michalik et al., 2002). In humans, the studies are almost exclusively 
focused on the PPARǄ roles during early placentation. It has been clearly established that all 
three PPARs can stimulate or inhibit the differentiation and/or proliferation of the villous 
cytotrophoblasts into syncytiotrophoblasts and the synthesis of chorionic gonadotrophic 
hormone and may hamper extravillous trophoblastic cell invasion (Fournier et al., 2007). It’s 
also clearly established that hCG gene expression is differentially regulated in the villous 
and extra-villous trophoblast lineages during their in vitro differentiation and modulated in 
an opposite way by PPAR (Handschuh et al., 2009). 
2.4.3 Roles of PPARs in the uptake and transport of trophoblastic lipids 
As one of the first functions described for PPARǄ in other tissues, trophoblastic lipid uptake 
and accumulation are also regulated in part by this factor (Schaiff et al., 2007). The PPARǄ 
ligands seem to increase the uptake and accumulation of the fatty acids in human placenta 
(Schaiff et al., 2005). This regulation is associated with an enhanced expression of 
adipophilin (fat droplet-associated protein) and fatty acid transport proteins (1 and 4) in 
human trophoblasts (Schaiff et al., 2005; Bildirici et al., 2003; Duttaroy, 2004). These results 
were confirmed by the in vivo activation of PPARǄ by its agonist rosiglitazone in mice, 
which also leads to the enhancement of the previous described genes plus two new ones 
involved in the lipid transport: S3-12 (plasma associated protein) and myocardial lipid 
droplet protein/MLDP (Schaiff et al., 2007). Taken together, these results confirm the results 
obtained on PPARǄ-null mutants: the absence of the lipid droplets normally present around 
the fetal vessels in the wild-type placenta (Barak et al., 1999). 
2.4.4 PPARs in placental inflammatory response and in the parturition signaling 
At this stage of our knowledge of PPARs, the most interesting results have been obtained 
with the study of their involvement in the inflammation process, which may be linked to 
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labor at term and also to the premature rupture of fetal membranes (Figure 2). Term labor is 
associated with an increase in proinflammatory proteins and cytokines such as IL1ǃ, IL6, 
IL8, IL10, and TNF-ǂ. This increase in proinflammatory proteins and cytokines induces 
uterine contractions. PPARǄ ligands have been demonstrated to inhibit the secretion of IL6, 
IL8, and TNF-ǂ in amnion and chorion (Lappas et al., 2006), highlighting the role of PPARs 
in the regulation of the inflammatory response in human gestational tissues and cells (Kniss, 
1999; Lappas et al., 2002; Ackerman et al., 2005; Berry et al., 2005). The parathyroid 
hormone-related protein (presenting a cytokine-like action) is involved in many processes 
during normal and pathological pregnancies, and is decreased by PPARǄ stimulation 
(Lappas & Rice, 2004), which also blocks proinflammatory cytokine release by adiponectin 
and leptin (Lappas et al., 2005). The production of prostaglandins by the endometrium, the 
myometrium, and the fetal membranes induces the contraction of the myometrium during 
labor. This generation of uterotonic prostaglandins correlates with the increased 
prostaglandin-endoperoxide synthase type 2/cyclooxygenase type 2 (COX-2) activity and 
the increased secretory phospholipase A2-IIA (sPLA2) mRNA, proteins and activities. By 
inhibiting the production of the COX-2 and sPLA2 in fetal membranes, PPARǄ promotes the 
quiescence of the uterus during gestation (Ackerman et al., 2005). The PPARǄ level of 
expression remains stable throughout gestation, except for the period just before labor, 
when its expression in fetal membranes declines. This reduction is coincidental with a  
 
Fig. 2. Schematic representation of PPARǄ implication in pregnancy maintenance and labor. 
IL1ǃ: Interleukin 1ǃ; IL6: Interleukin 6; IL8: Interleukin 8; IL10: Interleukin 10, TNFǂ: Tumor 
Necrosis Factor ǂ; COX2: Cyclo-oxygenase type 2; PLA2: Phospholipase A2; NF-κB: Nuclear 
Factor-Kappa B; MMP9: Matrix Metalloproteinase 9; 15dPGJ2: 15-Deoxy-Δ12, 14 
prostaglandin J2 (Borel et al., 2008). 
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relative increase in COX-2 expression (Dunn-Albanese et al., 2004). The PPAR action seems 
to be concentration-dependent. A small amount of 15dPGJ2 (<0.1 μM) acts through the 
PPARǄ signaling pathway, where at high concentration (1 μM) its actions are most probably 
mediated through other pathways: PPARǃ/ǅ and/or an inhibition of NF-κB independent of 
PPARs (Berry et al., 2005). Furthermore, 15dPGJ2 and troglitazone were also demonstrated 
to have some anti-inflammatory or apoptosis-induction specific effects by PPARǄ-
independent pathways (Lappas et al., 2006). 
2.4.5 PPARs in placental and amniotic membranes pathologies 
In contrast to the different roles described for PPARs during human placentation, only a few 
studies on PPARs and placental pathologies have been conducted. PPARs may be involved 
in the pathophysiology of gestational diabetes mellitus, intrauterine growth restriction and 
preeclampsia (Holdsworth-Carson et al., 2010). In choriocarcinoma and hydatiform moles, a 
downregulation of the PPARǄ expression is observed but this real influence needs to be 
elucidated (Capparuccia et al., 2002). The potential involvement of PPARǄ on preeclampsia 
is suggested by the fact that this pathology is associated with an increased peroxidation in 
trophoblasts (Roberts et al., 1999; Ware Branche et al., 1994). An overproduction of 15-HETE 
has also been noted, suggesting a deregulation of PPARǄ (Johnson et al., 1998). This can 
cause a strong transactivation of PPARǄ during early pregnancy, resulting in a reduction of 
extravillous trophoblastic invasion, one cellular explanation often cited in the 
physiopathology of preeclampsia (Schild et al., 2002; Fournier et al., 2002; Fournier et al., 
2008a). It is also established that deletion of PPARǄ, PPARǃ/ǅ, and some of their 
coactivators (PBP, PRIP, and RAP250) induce abnormal placental phenotypes (abruption, 
reduction of fetomaternal exchanges, and alterations of trophoblastic differentiation) in null 
mutants (Barak et al., 1999; Antonson et al., 2003; Zhu et al., 2000; Barak et al., 2002; Kuang 
et al., 2002; Nadra et al., 2006). Chromosomal and/or genetic alterations (point mutation or 
deletion) may occur for these genes, inducing human placental alterations. The placental 11ǃ 
hydroxysteroid dehydrogenase type 2 is a target gene of PPARs (Julan et al., 2005). This 
enzyme plays a key role in fetal development by controlling fetal exposure to maternal 
glucocorticoids. An abnormal regulation by PPARs may result in an absence of fetal 
protection. In the rat placental HRP-1 established cell line, the phthalate and derivatives 
transactivate PPARs (ǂ and Ǆ) induced an increase in uptake rates of fetal essential fatty acid 
and the transport of arachidonic and docosahexaenoic acid (Xu et al., 2005). If such a 
mechanism can be induced by the phthalates during human placentation, this may strongly 
affect the fetal essential fatty acid content during growth. 
Gestational diabetes is linked to impaired lipids metabolism (Capobianco et al., 2003) and 
the increase of PPARǄ observe in human trophoblastic cells culture might be involved in the 
impairment of placental development induced by high glucose conditions (Suwaki et al., 
2007). Decreased 15dPGJ2 in blood of diabetic mothers is also linked to a decrease in 
placental PPARǄ expression. The inhibition of PPARǄ results in an induction of a placental 
proinflammatory environment associated with an increase in nitrogen monoxide production 
and release, which can impair fetoplacental development (Jawerbaum et al., 2004; 
Jawerbaum & González, 2006; Jawerbaum & Capobianco , 2011). The PPAR regulation of 
inflammation may be very important in another obstetrical pathology of the amniotic 
membranes: the chorioamnionitis. This pathology, usually due to an ascendant colonization 
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of pathogenic microorganisms from the vagina to the uterus, is closely associated with 
preterm labor and premature rupture of membranes (chorion and amnion). These ruptures 
of membranes seem to arise from deregulated proinflammatory factor synthesis. It has 
already been reported in this pathology that IL1ǃ, IL6, IL8, TNF-ǂ, and prostaglandinE(2) 
show inadequate concentrations in placental membrane and in amniotic fluid (Willi et al., 
2002; Zaga et al., 2004; Jacobsson et al., 2005; Zaga-Clavellina et al., 2006). As PPARs may be 
involved in the occurrence and control of this inflammatory response, further studies are 
needed to assess their importance in this process and to find new possible therapeutic 
strategies to prevent this damaging pathology. 
More generally, the use of natural and synthetic PPAR ligands looks to be a promising way 
in preventing placental pathologies such as endometriosis, preeclampsia or diabetes 
(Giaginis et al., 2008). An interesting study also demonstrates that the reduction of LPS 
induction of cytokines is reduced by PPARǄ ligands in fetal membranes. Nevertheless, the 
few studies already conducted were done practically only on animal (rodent) models and 
looks to have positive effects on the pathologies (Toth et al., 2007). Till now, the major 
problem using, for example, TZD (thiazolidinediones) linking to the PPARǄ pathways still 
the numerous adverse effects of this kind of treatment (e.g., weight gain, anemia, 
leukopenia, etc.). Perhaps, at the level of clinician actual knowledge, PPARǄ and its ligands 
could be used in a first time, only as good early marker candidates for the diagnosis of 
pregnancy pathologies like, for example, preeclampsia. 
3. The liver x receptor (LXRs) 
First discovered and defined as orphan receptors, liver X receptors (LXRs) were 
subsequently identified as the nuclear receptor target of the cholesterol metabolites, 
oxysterols (Apfel et al., 1994; Janowski et al., 1996). LXR pathway regulates lipid metabolism 
and inflammation via both the induction and repression of target genes (Calkin & Tontonoz, 
2010) and have been identified in different species such as the vase tunicate, xenopus, 
zebrafish, mouse, rat, and humans. 
3.1 Nomenclature and structure of LXRs 
LXRǂ (NR1H3) and LXRǃ (NR1H2) belong to a subclass of the nuclear receptor superfamily, 
that form obligatory heterodimers with retinoid X receptor (RXR), the receptor of 9-cis 
retinoic acid. In humans LXRǂ and LXRǃ are encoded by two distinct genes located on 
chromosomes 11 and 19, respectively. LXR were initially isolated from a human liver cDNA 
library as orphan receptors. Later, oxysterols, which are oxidized derivatives of cholesterol, 
were identified as their natural ligands and the first physiological functions were associated 
with cholesterol homeostasis. By performing multiple LXR nucleotide/protein alignments 
of LXRs in different species, a strong interspecies identity (human, mouse, rat, bovine, 
≈87%) has been established, illustrating a strong evolutionary conservation among species 
by derivation from a common ancestor (Table 2). 
Similar to other nuclear receptors, both LXR isoforms comprise four distinct domains: 1) an 
amino-terminal activation domain (AF-1), recruiting ligand-independent co-activators 
(domain A/B), 2) a DNA-binding domain containing two zinc fingers (domain C), 3) a hinge 
domain, binding co-repressors in absence of ligand (domain D) and 4) a multi-functional 
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carboxy-terminal domain, required for dimerization, containing a hydrophobic ligand 
binding site and a transactivation domain (AF-2) recruiting co-activators (domain E/F) 
(Figure 1). Interestingly, even though both DNA and ligand-binding pockets share 80% 
identity, human and mouse LXRǃ are shorter than LXRǂ in their N-terminal domain (12 and 
11 amino acids, respectively) and longer in the hinge region (23 and 18 amino acids, 
respectively). This fact could account for the lack of redundancy in vivo, even though both 
LXR isoforms bind similar DNA sequences and ligands in vitro (Viennois et al., 2011). LXR ǂ, 
ǃ, translation produces proteins of 447, 461 amino acids, respectively, with a molecular 
weight of 55 kDa for both (Michael et al., 2005). LXRǂ exists in three variants originating 
from alternative promoter usage and mRNA splicing: LXRǂ1, LXRǂ2, and LXRǂ3 (Chen et 
al., 2005). 
 
Table 2. Percentage of nucleotide and amino acid identity between the human, mouse, rat, 
and bovine LXR sequences. No LXR ǂ1, ǂ2 and ǂ3 alignment was carried out owing to lack of 
data on different species. The different sequences came from Ensembl and were aligned 
with Genomatix software. 
3.2 LXR ligands 
As with PPARs, there are two kinds of ligands for the LXRs: natural and synthetic. The 
physiological LXR agonist ligands are oxysterols, oxidized metabolites of cholesterol. In 
mammals, there are two sources of plasmatic oxysterols, in vivo production by enzymatic or 
chemical pathways, and exogenous nutritional supply (Viennois et al., 2011). Natural 
activating oxysterols include 22(R) hydroxycholesterol in steroidogenic tissues, 24(S)-
hydroxycholesterol in brain and plasma, 24(S),25-epoxycholesterol mainly found in the liver 
and 27-hydroxycholesterol in macrophages. These oxysterols have been reported to activate 
both LXRǂ and LXRǃ (Janowski et al., 1996). Likewise, desmosterol, a cholesterol precursor 
produced from zymosterol, could also activate LXR (Yang et al., 2006). Molecules derived 
from the bile acid pathway in particular natural 6-hydroxylated bile acids have been 
proposed as putative ligands inducing transcriptional activity of LXRǂ (Song et al., 2000). 
Some ligands naturally present in the serum may also have an antagonistic effect on LXR as 
7-ketocholesterol (Song et al., 2001). 
Many pharmaceutical companies have screened potential LXR ligands. Among them 
T0901317 (Schultz et al., 2000) and GW3965 (Collins et al., 2002), two nonsteroidal synthetic 
LXR agonists, are commonly used in experimental studies. T0901317, in contrast with 
GW3965, is not completely selective for LXR (Viennois et al., 2011). 
3.3 LXR expression patterns 
LXR was initially described as being highly expressed in a restricted subset of tissues known 
to play an important role in lipid metabolism such as liver, small intestine, kidney, spleen and 
adipose tissue whereas LXRǃ was found to be ubiquitously expressed (Viennois et al., 2011). 
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In the human placenta, both LXRand LXRǃ have been identified as early as the 6th week 
of gestation and can also be detected during gestation (Marceau et al., 2005). Indeed, mRNA 
expression is lowest in the first and second trimester of pregnancy (25 and 24% of term for 
LXRǂ, 33 and 16% for LXRǃ, respectively). Expression levels in preterm and term placentae 
are similar to each other, but significantly higher than in the first two trimesters of gestation. 
The obligate heterodimeric partner of the LXRs, RXR, was found to be constitutively 
expressed throughout gestation (Plösch et al., 2010). Furthermore, both LXRs have been 
demonstrated to be expressed in choriocarcinoma trophoblast cell lines, e.g., JAR and BeWo 
(Weedon-Fekjaer et al., 2005). 
3.4 Implications of LXRs in placenta and fetal membranes 
3.4.1 Placental and amniotic presence of LXRs ligands 
Placenta is an organ in which oxysterols are detected at a high concentration range 
(Schroepfer, 2000). Moreover, oxysterols such as 25-hydroxycholesterol (25-OHC) and 7-
ketocholesterol (7-ketoC) circulate at low concentrations in normal conditions, but increase 
in maternal plasma as pregnancy advances (Aye et al., 2011). At low concentrations (2.5 µM) 
the oxysterol 22 (R)-OHC was shown to prevent first trimester extravillous cytotrophoblast 
invasion through the liver X receptor (LXR) which recognizes oxysterols as endogenous 
ligands (Pavan et al., 2004; Fournier et al., 2008b). Furthermore, the 7-ketocholesterol inhibit 
extravillous cytotrophoblast invasion. The role of LXR ligands in the placenta was 
confirmed using the LXR agonist T0901317, demonstrating the role of this nuclear receptor 
and its ligands in modulating the human trophoblast invasion (Pavan et al., 2004). 
3.4.2 Fundamental implications of LXRs during early placentation 
Little is known about the function of LXR during the placentation. A potential function of 
LXR in the placenta may be the regulation of cholesterol transport from the maternal to the 
fetal circulation. Indeed, cholesterol may be transported from the mother to the fetus to 
supplement the fetal cholesterol pool (Bełtowski & Semczuk, 2010). Conceptus implantation 
involves invasion of the uterine epithelium and the underlying stroma by extraembryonic 
trophoblast cells that undergo a complex process of proliferation, migration and 
differentiation. A specific feature of human placentation is the high degree of trophoblast 
invasion, greater than in other mammals. T0901317 has been shown to inhibit the 
invasiveness of cultured cytotrophoblast cells in vitro (Pavan et al., 2004). In addition, LXR 
mediates the inhibitory effect of oxidized LDL on trophoblast invasiveness. 
3.4.3 Roles of LXRs in the uptake and transport of trophoblastic lipids 
Compared with the liver, placenta secretes 50-200 times more fatty acid (Coleman & 
Haynes, 1987), indicating the importance of fatty acid as a mode of delivery of lipids to the 
fetus (Duttaroy, 2000). Noted that a new target gene, the long –chain acyl-coA synthetase 3 
(ACSL3) was recently identified to illustrate the role of LXR as a regulator in fatty acid 
metabolism (Weedson-Fekjaer et al., 2010a). LXR has been demonstrated to be expressed in 
the placenta and in trophoblast-like cell lines, e.g., JAR and BeWo (Peet et al., 1998; Weedon-
Fekjaer, 2005; Pavan et al., 2004). The increased fatty acid secretion by BeWo cells mediated 
by LXRs indicates its importance in placental lipid transport. Moreover, LXR activation in 
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trophoblasts would lead to increased expression of its target genes, e.g., ATP-binding 
cassette transporter A1 (ABCA1) and ATP-binding cassette transporter G1 (ABCG1). Based 
on the localization of the ABCG1 and ABCA1 proteins to the basolateral (fetal) side of the 
trophoblast, one could assume that LXR activation would increase cholesterol flux from the 
maternal to the fetal circulation. Depending on the lipidation status of acceptor particles in 
the fetal circulation, both ABCG1- or ABCA1-dependent pathways seem to be possible, or 
even a combination of both. Therefore, LXR activation may be considered as a stimulus for 
increased transport of maternal cholesterol via the placenta to the fetal circulation (Plösch et 
al.,2007). Added to the fact that ABCA1 and ABCG1 are present on the syncytiotropholast 
(the maternal facing placental membrane), these results identify the inducible placental 
cholesterol transport by LXR as a preventive mechanism of placental accumulation of 
cytotoxic oxysterols (Aye et al., 2010).  
3.4.4 LXRs in trophoblast invasion 
Human implantation involves invasion of the uterine wall by trophoblastic cells and 
remodeling of uterine arteries by extravillous cytotrophoblasts (Henry-Berger et al., 2008). 
Several lines of evidence support the involvement of the LXR pathway in trophoblast 
biology. Firstly, trophoblast invasion is accompanied by an increased degradation of 
extracellular matrix proteins by members of the matrix metalloproteinases (MMPs) family 
(Caniggia et al.,1997), and expression of matrix metalloprotease-9 (MMP9) is regulated in 
macrophages by a mechanism dependent on LXR activation (Castrillo et al., 2003); secondly, 
T0901317 and oxidized LDLs (oxLDL), rich in oxysterols, significantly reduce trophoblast 
invasion via a mechanism involving LXRǃ (Pavan et al., 2004; Fournier et al., 2008; Bełtowski 
& Semczuk, 2010). Recently Aye et al have shown that oxysterols inhibit syncytialisation 
and differentiation of term placental trophoblasts by activating LXRs. Excessive oxysterol 
exposure during pregnancy as a result of increased oxidative stress may, therefore, 
compromise placental formation and regeneration via inhibition of syncytialisation, thereby 
contributing to placental pathologies (Aye et al., 2011). 
3.4.5 LXRs in placental pathologies 
The pregnancy disease preeclampsia, a multisystemic disorder affecting about 5-10% of 
pregnancies towards the end of the second trimester of gestation, is still one of the leading 
causes of pregnancy-related maternal and fetal morbidity and mortality (Sibai et al., 2005; 
Myatt, 2002). Among its complications, intrauterine growth restriction and premature birth 
are of clinical relevance. Maternal predisposing factors such as diabetes, hypertension and 
obesity contribute to the consequences of this condition. Strong evidence supports that 
preeclampsia is generated by shallow invasion of the extravillous trophoblast into the 
decidua and an incomplete remodeling of the maternal uterine spiral arteries (Myatt, 2002). 
LXRǃ mediates the inhibitory effect of oxidized LDL on trophoblast invasiveness, thus LXR 
agonists might interfere with the implantation process (Fournier et al., 2008). Moreover, 
inefficient trophoblast invasion may lead to subsequent impairment of placental perfusion, 
which is a main pathogenetic factor in preeclampsia. Furthermore, LXR agonists reduce the 
synthesis and secretion of hCG from trophoblast cells, which is mandatory for maintaining 
pregnancy in the first trimester (Weedon-Fekjaer et al., 2005). An increase in LXR and 
ABCA1 transporter levels point to an important role of ligands such as the oxysterols, which 
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may be increased in preeclampsia (Plösch et al., 2010). A positive correlation between 
placental LXR mRNA expression and placental free fatty acids was found in preeclampsia 
(Weedon-Fekjaer et al., 2010b).  
Recently, T0901317 has been shown to increase the expression of endoglin, part of the 
transforming growth factor-ǃ receptor complex. Endoglin is highly expressed in 
syncytiotrophoblast and inhibits trophoblast invasion (Henry-Berger et al., 2008). The 
human endoglin gene promoter contains six putative LXRE sequences and at least one of 
them binds the LXR/RXR heterodimer to stimulate transcription in response to 22(R)-
hydroxycholesterol, T0901317 or synthetic RXR agonists (Henry-Berger et al., 2008). 
Interestingly, circulating endoglin level is increased in preeclampsia and may contribute to 
endothelial dysfunction associated with this disorder (Legry et al., 2008). Apart from 
stimulating endoglin, LXR agonists may reduce trophoblast invasiveness by down-
regulating MMP9, as has been demonstrated in macrophages (Castrillo et al., 2003). The 
demonstration that LXR together with ABCA1 can be regulated by hypoxia is another 
argument of the LXR involvement in preeclampsia, where the oxygen tension is described as 
abnormal (Plösch et al., 2010). 
4. Conclusion 
Since the discovery of the PPARs, there has been a marked increase in available data on their 
involvement in mammalian development. Concerning the placenta, all PPARs, but 
particularly PPARǄ, are essential for multiple physiological functions of the trophoblastic and 
amniotic parts, leading to major involvement of PPARs in the pathophysiology of gestational 
diseases. However, special care must be taken when this particular PPAR signalling cascade is 
involved, because part of the regulation may involve PPAR ligand signalling but may be 
transduced by independent nuclear receptor pathways. This last point introduces a new level 
of complexity in PPAR biology. It does not close preclusion of the eventual use of PPARs for 
therapeutic treatment during pregnancy, but future medical applications seem still to be a long 
way off. We can reasonably expect to see some obstetrical use of PPARs in diagnosis (detection 
of PPARs mutations in intrauterine growth retardation, predisposition of preeclampsia) and 
therapeutics (tocolysis or treatment of chorioamniotis). 
About LXR, a few recent publications show its involvement in obstetric pathologies such as 
preeclampsia, where he would reduce the invasiveness of extravillous trophoblast. Besides, 
the potential therapeutic application of LXR agonists may include increasing uterine 
contractility, (especially in conditions expected to increase cholesterol content in uterine 
myocytes, such as obesity, hypercholesterolemia or gestational diabetes mellitus) and 
stimulation of transplacental cholesterol transport for the prenatal treatment of inborn errors 
of cholesterol synthesis. 
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